Clinical trials: Myeloma, Plasma-Cell
Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care…
- Conditions
- Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Multiple Chronic Conditions
- Trial name
- NCT04663100
- Testing
- Patient-reported outcome measure, Comprehensive Medication Review, Pharmacist communication
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Tennessee
Multiple Myeloma
Feasibility Study of an ePRO Monitoring for Patients With Multiple Myeloma and Development of Item Lists
The trial is a feasibility study of a patient-reported outcome (PRO) monitoring for patients with multiple myeloma. Patients will report weekly PROs during treatment at our outpatient unit.
- Trial name
- NCT05036863
- Testing
- Weekly questionnaires
- Where
- Austria
- Volunteers
- 39 people
- Sponsor
- Medical University Innsbruck
Multiple Myeloma
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had…
- Trial name
- NCT05354557
- Testing
- Iberdomide
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients
This is a single arm, open-label, multicenter phase I study to assess the safety, tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR, i.e.
- Conditions
- Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- NCT04688853
- Testing
- TEG002
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Gadeta B.V.
Multiple Myeloma
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Primary Objective of the trial is to evaluate the efficacy and safety of Isa-VRd-based regimen in transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) patients receiving treatment in real-world clinical practice in…
- Trial name
- CHAMPION-01 (NCT07663253)
- Testing
- Isatuximab, Bortezomib, Lenalidomide
- Where
- 13 sites in China
- Volunteers
- 333 people
- Sponsor
- Shanghai Zhongshan Hospital
Bioequivalence
A Pilot Bioequivalence Study of Pomalidomide
Pomalidomide capsule were developed to offer an alternative to the marketed formulation, This pilot study was aim to pre-assess the bioequivalence of the capsule formulations under fasted condition.
- Trial name
- NCT03424928
- Testing
- Pomalidomide 4 MG Oral Capsule, Pomalidomide 4 MG Oral Capsule-Pomalyst
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005092
- Testing
- Cyclophosphamide, Psoralen, Thiotepa
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Neoplasms, Multiple Myeloma
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
The purpose of this study is to look at whether the combination of lower-dose chemotherapy with two chemotherapy (anti-cancer) drugs, called busulfan and melphalan, and an antibody medication called alemtuzumab (Campath®), can…
- Conditions
- Hematologic Neoplasms, Multiple Myeloma, Anemia, Aplastic, Hemoglobinuria, Paroxysmal
- Trial name
- ALBUM (NCT00997386)
- Testing
- busulfan, and melphalan, and alemtuzumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Arizona
Anemia, Leukemia
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
RATIONALE: Drugs such as epoetin alfa may relieve anemia caused by chemotherapy. The best time for giving epoetin alfa during chemotherapy is not yet known.
- Conditions
- Anemia, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003341
- Testing
- epoetin alfa, quality-of-life assessment
- Where
- 18 sites in United States
- Volunteers
- 275 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lyphoma, B-Cell, Leukemia, B-cell
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Background: Gene therapy is a way to treat or prevent disease using genes. It is monitored very closely by regulators because there can be long-term, unexpected side effects.
- Conditions
- Lyphoma, B-Cell, Leukemia, B-cell, Multiple Myeloma, Hematologic Malignancies
- Trial name
- NCT02473757
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin Lymphoma
A Rollover Study of CC-122
The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 [NCT01421524], CC-122-ST-002…
- Trial name
- NCT05688475
- Testing
- CC-122, Dexamethasone
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma, Frailty
Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
Frailty is dynamic and confers poor outcomes in elderly patients with newly diagnosed multiple myeloma (NDMM), mainly because of the high prevalence of treatment discontinuation due to intolerability.
- Trial name
- DynaFiT (NCT06099912)
- Where
- China
- Volunteers
- 131 people
- Sponsor
- FengYan Jin
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
This phase Ib/II trial compares the effect of teclistamab and pomalidomide to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of…
- Trial name
- NCT07463807
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
A Study in Leukemia Patients With Karonudib
The primary objective of this study is to determine safety and tolerability of Karonudib for the treatment of hematological malignancies.
- Trial name
- MAATEO (NCT04077307)
- Testing
- Karonudib
- Where
- 7 sites in Denmark, Serbia and 1 more
- Volunteers
- 50 people
- Sponsor
- Thomas Helleday Foundation
Multiple Myeloma
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
The patients are being offered a stem cell transplant. Stem cells are very early blood cells. They have not yet matured to become red or white blood cells or platelets.
- Trial name
- NCT01131169
- Testing
- busulfan, melphalan and fludarabine
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma
Multiple myeloma is a disease that resides primarily in the bone and has shown to be sensitive to radiation. Administration of a radiotherapy agent that targets the bone, such as Holmium-166-DOTMP, in conjunction with melphalan…
- Trial name
- NCT00039754
- Testing
- Holmium-166-DOTMP
- Sponsor
- Poniard Pharmaceuticals
Multiple Myeloma
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.
- Trial name
- NCT03943472
- Testing
- Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Myeloma, Lymphoma
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
The purpose of this study is to test whether the addition of the drug plerixafor to treatment with chemotherapy and G-CSF can better activate your bone marrow stem cells to improve the chances of transplant.
- Trial name
- NCT01095757
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Emory University
Multiple Myeloma and Plasma Cell Neoplasm
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00477971
- Testing
- filgrastim, dexamethasone, melphalan
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
The purpose of the study is to compare thalidomide + dexamethasone with bortezomib + dexamethasone in patients with multiple myeloma refractory to melphalan therapy.
- Trial name
- NCT00602511
- Testing
- Bortezomib, Thalidomide
- Where
- 27 sites in Denmark, Norway and 1 more
- Volunteers
- 300 people
- Sponsor
- Nordic Myeloma Study Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.